FDA explains why it rejected Vanda's stomach drug in late 2024

Zachary Brennan

Senior Editor

Rarely does the FDA publicly release its reasoning for rejecting a potential new drug. But for DC-based Vanda Pharmaceuticals’ gastroparesis drug, the FDA on Wednesday …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA explains why it rejected Vanda's stomach drug in late 2024

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

NIH payment cuts are 'reasoned and rational,' government says

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

Arcus touts early kidney cancer data as Gilead declines option

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FDA ex­plains why it re­ject­ed Van­da's stom­ach drug in late 2024

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA explains why it rejected Vanda's stomach drug in late 2024